VolitionRx (VNRX) News Today → Don’t expose yourself to stocks during the week (From DTI) (Ad) Free VNRX Stock Alerts $0.77 -0.03 (-3.75%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 5:36 AM | americanbankingnews.comVolitionRx (NYSE:VNRX) Rating Reiterated by Cantor FitzgeraldMay 16 at 12:39 PM | marketbeat.comCantor Fitzgerald Reiterates Overweight Rating for VolitionRx (NYSE:VNRX)Cantor Fitzgerald reissued an "overweight" rating and issued a $2.50 target price on shares of VolitionRx in a report on Thursday.May 15, 2024 | finance.yahoo.comVolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ...May 13, 2024 | washingtonpost.comVolitionRX: Q1 Earnings SnapshotMay 13, 2024 | prnewswire.comVolitionRx Limited Announces First Quarter 2024 Financial Results and Business UpdateMay 12, 2024 | americanbankingnews.comStockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)May 8, 2024 | prnewswire.comVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business UpdateApril 10, 2024 | marketbeat.comResearch Analysts Set Expectations for VolitionRx Limited's FY2024 Earnings (NYSE:VNRX)VolitionRx Limited (NYSE:VNRX - Free Report) - Equities researchers at Zacks Small Cap issued their FY2024 earnings per share estimates for shares of VolitionRx in a research report issued to clients and investors on Monday, April 8th. Zacks Small Cap analyst S. Ralston anticipates that the compaApril 9, 2024 | marketbeat.comVolitionRx Limited Forecasted to Post Q1 2024 Earnings of ($0.11) Per Share (NYSE:VNRX)VolitionRx Limited (NYSE:VNRX - Free Report) - Equities research analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for shares of VolitionRx in a research report issued to clients and investors on Monday, April 8th. Zacks Small Cap analyst S. Ralston anticipates that the companyApril 8, 2024 | msn.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...April 8, 2024 | finance.yahoo.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for SepsisMarch 27, 2024 | marketbeat.comVolitionRx's (VNRX) Overweight Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $2.50 price objective on shares of VolitionRx in a report on Wednesday.March 26, 2024 | marketbeat.comVolitionRx (NYSE:VNRX) Releases Earnings ResultsVolitionRx (NYSE:VNRX - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.11) EPS for the quarter. VolitionRx had a negative net margin of 5,201.69% and a negative return on equity of 7,185.73%.March 25, 2024 | msn.comVNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023March 25, 2024 | prnewswire.comVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business UpdateMarch 22, 2024 | benzinga.comEarnings Outlook For VolitionRXMarch 21, 2024 | prnewswire.comVolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business UpdateMarch 21, 2024 | finanznachrichten.deVolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | markets.businessinsider.comVolitionRx Names Andrew Retter Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comVolition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | money.usnews.comVolitionRX LtdFebruary 22, 2024 | benzinga.comVolitionRX Stock (AMEX:VNRX), Short Interest ReportJanuary 2, 2024 | msn.comVolitionRx stock soars after company discloses $13M in milestone paymentsJanuary 2, 2024 | realmoney.thestreet.comVolitionRx milestone payment 'important step forward,' says EF HuttonNovember 17, 2023 | finance.yahoo.comVolition Presents at the 5th Annual Congress of the International Liquid Biopsy SocietyNovember 8, 2023 | proactiveinvestors.comVolitionRx to host Q3 earnings call on November 15October 28, 2023 | markets.businessinsider.comVolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s PerspectiveSeptember 1, 2023 | marketbeat.comVolitionRx Limited (NYSE:VNRX) Director Martin Charles Faulkes Acquires 9,716 SharesVolitionRx Limited (NYSE:VNRX - Get Free Report) Director Martin Charles Faulkes bought 9,716 shares of the stock in a transaction dated Thursday, August 31st. The shares were acquired at an average price of $1.28 per share, with a total value of $12,436.48. Following the completion of the purchase, the director now directly owns 1,673,532 shares of the company's stock, valued at $2,142,120.96. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Don’t expose yourself to stocks during the week (Ad)The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal. Click here and I’ll give you all the details. VNRX Media Mentions By Week VNRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VNRX News Sentiment▼0.740.42▲Average Medical News Sentiment VNRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VNRX Articles This Week▼80▲VNRX Articles Average Week Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TKNO News ABIO News ICCC News AWH News OCX News CDIO News ACHV News TOI News RLYB News NVNO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VNRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our Partners[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford Club41 banks launch ‘crypto dollar’Stansberry ResearchHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
